China Medical System Holdings announced that turnover for the six months to Jun, 30 2026 rose 12.5 % year on year to about 865 million Singapore dollars, driven by expanding sales of innovative and exclusive medicines.

Gross profit increased 10.7 % to roughly 619 million Singapore dollars, while profit for the period grew 4.3 % to nearly 187 million Singapore dollars.

The board declared an interim dividend of RMB 0.1634 per share, equal to approximately 0.031 Singapore dollars, a 5.1 % increase from a year earlier. Payment is scheduled for Sep, 8 2026 to shareholders on record as of Sep, 1 2026.

At end-June the group held cash and bank balances of about 495 million Singapore dollars. During the half, it repurchased roughly 6.4 million shares for an aggregate HK$ 67.9 million, equal to around 11 million Singapore dollars.

Sales of innovative and exclusive products advanced 19.7 % to RMB 1.70 billion, accounting for 37.7 % of total turnover. Three innovative drugs were approved in China during the period, five more are under new-drug application review, and three self-developed products received investigational new drug clearance.

The company’s specialty skin-health unit, Dermavon, posted a 59.1 % revenue rise to RMB 792.5 million and is being prepared for a separate listing in Hong Kong.

Management said the group will continue to pursue a dual-track strategy of in-house and collaborative R&D while expanding its international business centred in Singapore.